| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $201,352,952 ) (Continued on the next page) |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299449 | Computational Approaches to Reconstruct the Evolutionary History of Cancer Metastases | 000 | 1 | NIH | 5/5/2026 | $688,073 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA293361 | Modulation of the tumor microenvironment by Fusobacterium nucleatum and co-infecting microbes in colorectal cancer | 000 | 1 | NIH | 4/2/2026 | $660,541 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31AR087163 | Investigating the role of O-GlcNAc in silencing retrotransposons in the skin | 001 | 1 | NIH | 5/21/2026 | $0 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31AR087163 | Investigating the role of O-GlcNAc in silencing retrotransposons in the skin | 000 | 1 | NIH | 5/14/2026 | $38,189 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269489 | Molecular Mechanisms of Bladder Cancer Immunometabolism | 000 | 4 | NIH | 2/27/2026 | $480,324 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K08CA293160 | Evaluating Dietary Change and a Mediterranean Diet Intervention Among Medically Underserved Men with Prostate Cancer | 000 | 2 | NIH | 6/30/2026 | $209,909 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21MD021573 | Driving Wellness: A Feasibility Trial of a Multi-Level Health Behavior Intervention for Truck Drivers | 000 | 1 | NIH | 7/30/2026 | $260,767 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K01AG088489 | Impact and therapeutic effects of selective TERT activation in Alzheimers disease | 000 | 1 | NIH | 7/28/2026 | $100,802 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA315499 | Leveraging tobacco quitlines to disseminate lung cancer screening educational materials for persons who smoke | 000 | 1 | NIH | 7/20/2026 | $667,282 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA299578 | Unraveling the Interplay: Microbiome, p16 Expression, High-Risk HPV Infection, and Clinical Outcomes in Penile Cancer Across Diverse Patient Cohorts with Varied Mortality and Incidence Profiles | 000 | 1 | NIH | 7/30/2026 | $427,249 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA269622 | An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma | 000 | 4 | NIH | 2/27/2026 | $395,807 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269646 | Targeting ferroptosis in cancer therapy | 001 | 4 | NIH | 4/16/2026 | $49,400 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA276779 | Evaluation of T follicular regulatory cells as novel cellular targets of cancer immunotherapy | 001 | 5 | NIH | 6/30/2026 | $417,352 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269646 | Targeting ferroptosis in cancer therapy | 000 | 4 | NIH | 1/23/2026 | $444,596 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA270010 | Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer | 001 | 4 | NIH | 4/16/2026 | $47,386 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA270010 | Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer | 000 | 4 | NIH | 1/20/2026 | $426,474 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AI192472 | Dissecting a New Pyroptotic Mechanism Driven by Gasdermin A Activation | 000 | 1 | NIH | 7/9/2026 | $577,181 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL179815 | Deciphering the role of GFPT2 in radiation-induced cardiovascular disease | 000 | 2 | NIH | 7/31/2026 | $717,760 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P50CA302482 | MD Anderson Sarcoma SPORE | 000 | 2 | NIH | 9/17/2026 | $1,813,200 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P01CA296429 | Mechanisms of Bladder Cancer Development and Its Therapeutic Vulnerabilities to Preventive and Interventive Therapy. | 000 | 2 | NIH | 8/25/2026 | $2,005,189 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299696 | Decoding the co-evolution of cancer subclones and their ecosystem in TNBC multi-organ metastasis | 000 | 2 | NIH | 3/3/2026 | $676,584 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS146081 | Targeting RNF2 to Synergize with Oncolytic Immunovirotherapy to Induce Anti-Cancer Immunity in Medulloblastoma | 000 | 1 | NIH | 5/1/2026 | $421,361 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA315771 | Advancing TGFβ-Resistant CAR-NK Cell Therapy for Acute Myeloid Leukemia | 000 | 1 | NIH | 8/10/2026 | $387,156 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31CA310040 | Targeting CAMKK2 for the treatment of advanced prostate cancer | 001 | 1 | NIH | 8/11/2026 | $0 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31CA310040 | Targeting CAMKK2 for the treatment of advanced prostate cancer | 000 | 1 | NIH | 8/11/2026 | $50,114 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21HD119755 | CHAMP1 and mitochondria | 000 | 1 | NIH | 6/23/2026 | $451,000 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA315524 | PMN-MDSC in bone-TME of prostate cancer bone metastasis | 000 | 1 | NIH | 8/20/2026 | $586,101 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA307595 | Drug-loaded degradable biopolymeric scaffolds for augmenting preoperative liver growth | 000 | 1 | NIH | 3/30/2026 | $680,129 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA311472 | Disrupting ATF3/CGRP-IL-6 Neuroimmune Feedback to Overcome Neural Injury–Driven Immunotherapy Resistance in cSCC | 000 | 1 | NIH | 7/3/2026 | $645,865 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM159819 | Statistical methods to delineate the spatial and temporal pattern of cell-cell interactions in Spatial Transcriptomics data | 000 | 2 | NIH | 8/13/2026 | $449,625 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA303638 | Efficient Measurement and Characterization of Genetic Interactions in Cancer Cells | 000 | 2 | NIH | 7/27/2026 | $370,173 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA294088 | Decipher dose accumulation for online adaptive radiotherapy | 000 | 1 | NIH | 8/31/2026 | $425,410 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA309007 | Clonal Evolution and Immune Dysregulation in AML patients treated with Venetoclax and Azacitidine after Allogeneic Stem Cell Transplantation | 000 | 1 | NIH | 7/1/2026 | $421,685 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA312836 | Deciphering the Role of Tumor Suppressor Gene Deficiencies in Modulating PDAC Response to Oncogenic KRAS Inhibition and Immunotherapy | 000 | 1 | NIH | 5/7/2026 | $141,195 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R00CA296940 | Adverse gut microbiome promotes resistance immune checkpoint inhibitors via chronic inflammation | 000 | 2 | NIH | 4/17/2026 | $248,658 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA307597 | Delineating the role of TREM2 in chronic pancreatitis | 000 | 1 | NIH | 6/9/2026 | $374,006 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA317339 | Photoacoustic molecular imaging for planning of neoadjuvant antibody-drug-conjugate treatment of triple negative breast cancer | 000 | 1 | NIH | 7/20/2026 | $421,685 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA304638 | Ultrasound-guided cancer immunotherapy with targeted nanodroplets | 000 | 1 | NIH | 6/16/2026 | $421,685 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA301423 | Elucidating roles of the CD24 ligand in early lung cancer development, immune evasion and response to KRAS-targeted therapy | 000 | 1 | NIH | 6/16/2026 | $669,540 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA301148 | Targeting disulfidptosis in cancer: mechanisms and preclinical translation | 000 | 1 | NIH | 6/19/2026 | $621,632 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | T32CA101642 | Training of Academic Gynecologic Oncologists | 000 | 21 | NIH | 7/3/2026 | $567,034 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA307210 | Illuminating the Immune Dynamics of Metastatic Renal Cell Carcinoma to Bone | 000 | 1 | NIH | 7/28/2026 | $579,658 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA308198 | A Novel Cell Stress Response Mechanism in Pancreatic Cancer | 000 | 1 | NIH | 7/29/2026 | $633,089 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA317515 | Multi-ancestry study of mammographic density | 000 | 1 | NIH | 7/23/2026 | $717,715 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA316177 | Advancing Transfer Learning Using Surrogates, Family History, and Prior Models. | 000 | 1 | NIH | 7/14/2026 | $500,384 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA315487 | Lung cell transplantation for drug induced pulmonary fibrosis in cancer patients | 000 | 1 | NIH | 8/3/2026 | $645,186 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA310933 | NK Cell Engineering to Target Intracellular Antigens in AML | 000 | 1 | NIH | 7/22/2026 | $442,146 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA302934 | Defining biomarkers and overcoming resistance to DLL3-targeting immune therapies in lung cancer | 000 | 1 | NIH | 7/23/2026 | $671,740 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | UM1CA321705 | OPTIMA: Oncology Precision Trials using Individualized Model Avatars | 000 | 1 | NIH | 7/23/2026 | $1,500,000 |
|
